Concentration): Threshold below which no adverse environmental effects are expected.

ICH Q3E Draft Guideline: Ongoing harmonization effort for ERA requirements across ICH regions.

These definitions provide the scientific and regulatory framework for ERA submissions worldwide.

Global ERA Frameworks and Regulatory Requirements

ERA obligations differ across regions but share common scientific principles:

• EMA (EU): Requires ERA submission for all new marketing authorization applications (MAAs) under Directive 2001/83/EC. Guidelines detail Phase I and II methodologies.
• FDA (US): Environmental assessments required under 21 CFR Part 25 unless categorical exclusions apply. Often focused on manufacturing and API discharges.
• CDSCO (India): Growing emphasis on ERA as part of API manufacturing approvals and ESG-linked compliance, especially for wastewater discharges.
• ROW Markets: Canada, Japan, and China are developing ERA frameworks aligning with EU and US standards.

RA professionals must integrate ERA data into CTD Module 1 and supporting annexes for compliance across regions.

Processes and Workflow for Environmental Risk Assessments

An ERA follows a stepwise workflow:

1. Substance Identification: Characterize API, metabolites, and impurities relevant to environmental exposure.
2. Phase I Screening: Calculate PEC in surface water, soil, and sediments based on patient usage and excretion data.
3. Phase II Tier A/B Studies: Conduct laboratory and field studies to assess PBT properties.
4. Risk Characterization: Compare PEC with PNEC values to determine environmental risk quotient.
5. Mitigation Strategies: Propose measures such as improved wastewater treatment, eco-design of molecules, or controlled disposal programs.
6. Dossier Submission: Include ERA report in CTD/eCTD submission (Module 1.6 for EMA).
7. Post-Marketing Surveillance: Monitor API residues in the environment and update ERA data when new information emerges.

This structured approach ensures regulatory compliance and environmental protection.

Case Study 1: ERA for Antimicrobial Drug

Case: A company submitted an ERA for a new antibiotic in 2022.

• Challenge: Concerns about antimicrobial resistance in wastewater ecosystems.
• Action: Conducted advanced microbial resistance modeling and wastewater monitoring studies.
• Outcome: EMA approved the drug with conditions for post-marketing environmental monitoring.
• Lesson Learned: Antibiotic ERAs require additional scrutiny due to AMR risks.

Case Study 2: FDA ERA Categorical Exclusion

Case: A US company applied for a small-volume injectable drug with minimal environmental release.

• Challenge: Determining if ERA obligations applied.
• Action: Submitted request for categorical exclusion under 21 CFR Part 25.
• Outcome: FDA granted exclusion, avoiding full ERA submission.
• Lesson Learned: Early classification can streamline FDA ERA obligations.

Tools, Templates, and Systems Used

Effective ERA compliance requires specialized resources:

• PEC/PNEC Calculation Templates: Standard spreadsheets for modeling environmental exposure.
• OECD Test Guidelines: Laboratory protocols for assessing persistence, bioaccumulation, and toxicity.
• IUCLID & ECHA Databases: Tools for data submission and chemical hazard reference.
• Regulatory Information Management (RIM) Systems: Tracking ERA submissions across multiple jurisdictions.
• Post-Market Monitoring Platforms: Systems to capture real-world environmental impact data.

These tools ensure consistency, transparency, and inspection readiness for ERA submissions.

Common Challenges and Best Practices

RA professionals face recurring challenges in ERA design and submission:

• Data Gaps: Lack of environmental fate data for certain APIs complicates PEC/PNEC modeling.
• Global Variability: Differences in EU, US, and Indian ERA frameworks add complexity to submissions.
• Manufacturing Discharges: API residues from production facilities create compliance risks.
• Resource Burden: Conducting ERA studies adds significant time and cost to development programs.

Best practices include starting ERA planning early in drug development, engaging with regulators, using harmonized OECD test protocols, and implementing supplier-level compliance agreements.

Latest Updates and Strategic Insights

By 2025, ERA compliance has expanded beyond traditional obligations:

• ICH Q3E: Draft guideline moving toward harmonized ERA requirements across ICH regions.
• Antimicrobial ERA Focus: Global regulators prioritizing environmental AMR risks in ERA reviews.
• Digital Modeling Tools: AI-driven PEC/PNEC simulations accelerating risk characterization.
• ESG Integration: ERA results now disclosed in ESG reports as evidence of environmental stewardship.
• Public Transparency: EMA and ECHA publishing ERA data to enhance public trust in pharma sustainability.

Strategically, RA professionals must integrate ERA obligations with corporate ESG goals and prepare for increased transparency in environmental compliance.

Conclusion

Environmental Risk Assessments are essential to safeguard ecosystems while enabling pharmaceutical innovation. By mastering global frameworks, harmonizing submissions, and leveraging advanced modeling tools, RA professionals can ensure compliance, mitigate risks, and support ESG reporting. In 2025 and beyond, ERAs will play a critical role in pharma’s regulatory and sustainability strategy, aligning public health with environmental responsibility.